Altogether, the overall relevance of PAPBC1, RPS13, and PSMA1 in MG appears uncertain and it would be premature to regard them as novel targets of non-AChR autoantibodies in patients with MG. The gene discussed is PSMA1; the disease is myasthenia gravis.